The U.S. Food and Drug Administration (FDA) has issued a consumer safety alert after nearly 12 million cartons of Rohto eye drops were voluntarily recalled due to concerns that the products may not meet required sterility standards. The recall affects several popular over-the-counter eye care products distributed nationwide and serves as a precaution to protect consumers from potential eye infections.
The FDA classified the action as a Class II recall, meaning use of the affected products could result in temporary or medically reversible health effects, although the likelihood of serious harm is considered low.
Millions of Eye Drop Cartons Included
According to the FDA, the recall involves approximately 11.96 million cartons of Rohto Cooling Eye Drops manufactured in Vietnam and distributed across the United States. Regulators said the products were recalled because of a “lack of assurance of sterility,” indicating the manufacturer could not confirm that the eye drops were completely free of microbial contamination.
Since ophthalmic products are applied directly to the eyes, sterility is a critical safety requirement. Even a small amount of contamination can increase the risk of irritation or infection.
Products Covered by the Recall
The recall includes multiple Rohto eye drop products commonly used to relieve dry eyes, redness, and irritation. Among the affected products are:
- Rohto ALL-IN-ONE
- Rohto Max Strength
- Rohto Max Strength Twin Pack
- Rohto Optic Glow
- Rohto Digi Eye
- Rohto Dry Aid
- Rohto Dry Aid Twin Pack
- Rohto Cool Relief
Consumers should review the lot numbers and expiration dates listed in the FDA recall notice to determine whether their products are affected.
FDA Urges Consumers to Stop Using Recalled Products
The FDA advises consumers to discontinue use of any recalled Rohto eye drops immediately. Customers who purchased the affected products should dispose of them safely or return them to the place of purchase if a refund or replacement is available.
Although no widespread reports of serious injuries have been announced in connection with the recall, contaminated eye drops can pose health risks because they come into direct contact with the eye. Individuals who experience redness, pain, swelling, blurred vision, or signs of an eye infection after using the products should seek medical attention promptly.
Why Sterility Is Essential
Sterility is one of the most important quality standards for eye care products. Unlike many other over-the-counter medications, eye drops bypass many of the body’s natural defenses, making contamination a potential source of bacterial or fungal infections.
For that reason, manufacturers are required to maintain strict production and quality control measures to ensure ophthalmic products remain sterile throughout the manufacturing and packaging process.
Continued Focus on Eye Product Safety
The Rohto recall is part of the FDA’s ongoing efforts to monitor the safety and quality of eye care products sold in the United States. In recent years, regulators have taken several enforcement actions involving ophthalmic products after manufacturing concerns raised questions about product sterility.
Consumers who believe they have one of the recalled Rohto eye drop products are encouraged to check the FDA’s official recall information, stop using the product if it is included in the recall, and follow the manufacturer’s instructions for returns or disposal.
As the FDA continues to oversee the recall process, officials emphasize that consumers should remain alert to product safety notices and always follow recall guidance to help reduce the risk of preventable eye injuries or infections.
To know more Health news